Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
7,711
archived clinical trials in
Depression

Efficacy and Safety of Lu AA21004 in Adults With Major Depressive Disorder
A Phase 3, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed-Dose Study Comparing the Efficacy and Safety of 2 Doses (10 and 15 mg) of Lu AA21004 in Acute Treatment of Adults With Major Depressive Disorder
Status: Archived
Clinical Trial Facility
mi
from
St Louis, MO
Efficacy and Safety of Lu AA21004 in Adults With Major Depressive Disorder
A Phase 3, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed-Dose Study Comparing the Efficacy and Safety of 2 Doses (10 and 15 mg) of Lu AA21004 in Acute Treatment of Adults With Major Depressive Disorder
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
St Louis, MO
Efficacy and Safety of Lu AA21004 in Adults With Major Depressive Disorder
A Phase 3, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed-Dose Study Comparing the Efficacy and Safety of 2 Doses (10 and 15 mg) of Lu AA21004 in Acute Treatment of Adults With Major Depressive Disorder
Status: Archived
Clinical Trial Facility
mi
from
Henderson, NV
Efficacy and Safety of Lu AA21004 in Adults With Major Depressive Disorder
A Phase 3, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed-Dose Study Comparing the Efficacy and Safety of 2 Doses (10 and 15 mg) of Lu AA21004 in Acute Treatment of Adults With Major Depressive Disorder
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Henderson, NV
Efficacy and Safety of Lu AA21004 in Adults With Major Depressive Disorder
A Phase 3, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed-Dose Study Comparing the Efficacy and Safety of 2 Doses (10 and 15 mg) of Lu AA21004 in Acute Treatment of Adults With Major Depressive Disorder
Status: Archived
Clinical Trial Facility
mi
from
Lebanon, NH
Efficacy and Safety of Lu AA21004 in Adults With Major Depressive Disorder
A Phase 3, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed-Dose Study Comparing the Efficacy and Safety of 2 Doses (10 and 15 mg) of Lu AA21004 in Acute Treatment of Adults With Major Depressive Disorder
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Lebanon, NH
Efficacy and Safety of Lu AA21004 in Adults With Major Depressive Disorder
A Phase 3, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed-Dose Study Comparing the Efficacy and Safety of 2 Doses (10 and 15 mg) of Lu AA21004 in Acute Treatment of Adults With Major Depressive Disorder
Status: Archived
Clinical Trial Facility
mi
from
Lima, OH
Efficacy and Safety of Lu AA21004 in Adults With Major Depressive Disorder
A Phase 3, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed-Dose Study Comparing the Efficacy and Safety of 2 Doses (10 and 15 mg) of Lu AA21004 in Acute Treatment of Adults With Major Depressive Disorder
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Lima, OH
Efficacy and Safety of Lu AA21004 in Adults With Major Depressive Disorder
A Phase 3, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed-Dose Study Comparing the Efficacy and Safety of 2 Doses (10 and 15 mg) of Lu AA21004 in Acute Treatment of Adults With Major Depressive Disorder
Status: Archived
Clinical Trial Facility
mi
from
Philadelphia, PA
Efficacy and Safety of Lu AA21004 in Adults With Major Depressive Disorder
A Phase 3, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed-Dose Study Comparing the Efficacy and Safety of 2 Doses (10 and 15 mg) of Lu AA21004 in Acute Treatment of Adults With Major Depressive Disorder
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Philadelphia, PA
Efficacy and Safety of Lu AA21004 in Adults With Major Depressive Disorder
A Phase 3, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed-Dose Study Comparing the Efficacy and Safety of 2 Doses (10 and 15 mg) of Lu AA21004 in Acute Treatment of Adults With Major Depressive Disorder
Status: Archived
Clinical Trial Facility
mi
from
Providence, RI
Efficacy and Safety of Lu AA21004 in Adults With Major Depressive Disorder
A Phase 3, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed-Dose Study Comparing the Efficacy and Safety of 2 Doses (10 and 15 mg) of Lu AA21004 in Acute Treatment of Adults With Major Depressive Disorder
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Providence, RI
Efficacy and Safety of Lu AA21004 in Adults With Major Depressive Disorder
A Phase 3, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed-Dose Study Comparing the Efficacy and Safety of 2 Doses (10 and 15 mg) of Lu AA21004 in Acute Treatment of Adults With Major Depressive Disorder
Status: Archived
Clinical Trial Facility
mi
from
Charleston, SC
Efficacy and Safety of Lu AA21004 in Adults With Major Depressive Disorder
A Phase 3, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed-Dose Study Comparing the Efficacy and Safety of 2 Doses (10 and 15 mg) of Lu AA21004 in Acute Treatment of Adults With Major Depressive Disorder
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Charleston, SC
Efficacy and Safety of Lu AA21004 in Adults With Major Depressive Disorder
A Phase 3, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed-Dose Study Comparing the Efficacy and Safety of 2 Doses (10 and 15 mg) of Lu AA21004 in Acute Treatment of Adults With Major Depressive Disorder
Status: Archived
Clinical Trial Facility
mi
from
Nashville, TN
Efficacy and Safety of Lu AA21004 in Adults With Major Depressive Disorder
A Phase 3, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed-Dose Study Comparing the Efficacy and Safety of 2 Doses (10 and 15 mg) of Lu AA21004 in Acute Treatment of Adults With Major Depressive Disorder
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Nashville, TN
Efficacy and Safety of Lu AA21004 in Adults With Major Depressive Disorder
A Phase 3, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed-Dose Study Comparing the Efficacy and Safety of 2 Doses (10 and 15 mg) of Lu AA21004 in Acute Treatment of Adults With Major Depressive Disorder
Status: Archived
Clinical Trial Facility
mi
from
Austin, TX
Efficacy and Safety of Lu AA21004 in Adults With Major Depressive Disorder
A Phase 3, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed-Dose Study Comparing the Efficacy and Safety of 2 Doses (10 and 15 mg) of Lu AA21004 in Acute Treatment of Adults With Major Depressive Disorder
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Austin, TX
Efficacy and Safety of Lu AA21004 in Adults With Major Depressive Disorder
A Phase 3, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed-Dose Study Comparing the Efficacy and Safety of 2 Doses (10 and 15 mg) of Lu AA21004 in Acute Treatment of Adults With Major Depressive Disorder
Status: Archived
Clinical Trial Facility
mi
from
Ogden, UT
Efficacy and Safety of Lu AA21004 in Adults With Major Depressive Disorder
A Phase 3, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed-Dose Study Comparing the Efficacy and Safety of 2 Doses (10 and 15 mg) of Lu AA21004 in Acute Treatment of Adults With Major Depressive Disorder
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Ogden, UT
Efficacy and Safety of Lu AA21004 in Adults With Major Depressive Disorder
A Phase 3, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed-Dose Study Comparing the Efficacy and Safety of 2 Doses (10 and 15 mg) of Lu AA21004 in Acute Treatment of Adults With Major Depressive Disorder
Status: Archived
Clinical Trial Facility
mi
from
Milwaukee, WI
Efficacy and Safety of Lu AA21004 in Adults With Major Depressive Disorder
A Phase 3, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed-Dose Study Comparing the Efficacy and Safety of 2 Doses (10 and 15 mg) of Lu AA21004 in Acute Treatment of Adults With Major Depressive Disorder
Status: Archived
Updated: 1/1/1970
Clinical Trial Facility
mi
from
Milwaukee, WI
Treatment of Anxiety/Depression and Pain Through Relaxation Yoga for Patient With Cystic Fibrosis (CF)
Treatment of Anxiety/Depression and Pain Through Relaxation Yoga for Patient With CF
Status: Archived
Children's Hospital/USC School of Medicine
mi
from
Los Angeles, CA
Treatment of Anxiety/Depression and Pain Through Relaxation Yoga for Patient With Cystic Fibrosis (CF)
Treatment of Anxiety/Depression and Pain Through Relaxation Yoga for Patient With CF
Status: Archived
Updated: 1/1/1970
Children's Hospital/USC School of Medicine
mi
from
Los Angeles, CA
Vitamin D for Improving Metabolic Control and Depressive Symptoms
Vitamin D for Improving Metabolic Control and Depressive Symptoms in Women With Diabetes; The Sunshine Study
Status: Archived
Loyola University Medical Center
mi
from
Proviso, IL
Vitamin D for Improving Metabolic Control and Depressive Symptoms
Vitamin D for Improving Metabolic Control and Depressive Symptoms in Women With Diabetes; The Sunshine Study
Status: Archived
Updated: 1/1/1970
Loyola University Medical Center
mi
from
Proviso, IL
Sexual Health on Antidepressants Through Physical Exercise
Sexual Health on Antidepressants Through Physical Exercise
Status: Archived
University of Texas at Austin
mi
from
Austin, TX
Sexual Health on Antidepressants Through Physical Exercise
Sexual Health on Antidepressants Through Physical Exercise
Status: Archived
Updated: 1/1/1970
University of Texas at Austin
mi
from
Austin, TX
Family Therapy as Hospital Aftercare for Adolescent Suicide Attempters
Family Therapy as Hospital Aftercare for Adolescent Suicide Attempters
Status: Archived
Children's Hospital at Downstate
mi
from
Brooklyn, NY
Family Therapy as Hospital Aftercare for Adolescent Suicide Attempters
Family Therapy as Hospital Aftercare for Adolescent Suicide Attempters
Status: Archived
Updated: 1/1/1970
Children's Hospital at Downstate
mi
from
Brooklyn, NY
Ketamine for Low Mood States in the ER
Low Dose Ketamine for Low Mood States: An Emergency Department Feasibility Study for Depressed Patients
Status: Archived
Yale University School of Medicine
mi
from
New Haven, CT
Ketamine for Low Mood States in the ER
Low Dose Ketamine for Low Mood States: An Emergency Department Feasibility Study for Depressed Patients
Status: Archived
Updated: 1/1/1970
Yale University School of Medicine
mi
from
New Haven, CT
Middle School Matters Study
Prevention of Depression Within Salient Adolescent Contexts
Status: Archived
Seattle Children's
mi
from
Seattle, WA
Middle School Matters Study
Prevention of Depression Within Salient Adolescent Contexts
Status: Archived
Updated: 1/1/1970
Seattle Children's
mi
from
Seattle, WA
Feasibility Study of Duloxetine in the Treatment of Depression in Patients With Traumatic Brain Injury (TBI)
Prevention of Depression and Enhancement of Cognitive Recovery Following Traumatic Brain Injury With Duloxetine
Status: Archived
Rehabilitation Hospital of Indiana
mi
from
Indianapolis, IN
Feasibility Study of Duloxetine in the Treatment of Depression in Patients With Traumatic Brain Injury (TBI)
Prevention of Depression and Enhancement of Cognitive Recovery Following Traumatic Brain Injury With Duloxetine
Status: Archived
Updated: 1/1/1970
Rehabilitation Hospital of Indiana
mi
from
Indianapolis, IN
Efficacy, Safety and Tolerability of CX157 in Treatment Resistant Depression
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Assessment of the Efficacy, Safety and Tolerability of CX157 Modified Release Tablet, 125 mg Twice Per Day in Subjects With Treatment Resistant Depression
Status: Archived
Synergy Escondido
mi
from
Escondido, CA
Efficacy, Safety and Tolerability of CX157 in Treatment Resistant Depression
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Assessment of the Efficacy, Safety and Tolerability of CX157 Modified Release Tablet, 125 mg Twice Per Day in Subjects With Treatment Resistant Depression
Status: Archived
Updated: 1/1/1970
Synergy Escondido
mi
from
Escondido, CA
Efficacy, Safety and Tolerability of CX157 in Treatment Resistant Depression
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Assessment of the Efficacy, Safety and Tolerability of CX157 Modified Release Tablet, 125 mg Twice Per Day in Subjects With Treatment Resistant Depression
Status: Archived
Synergy Clinical Research Center
mi
from
National City, CA
Efficacy, Safety and Tolerability of CX157 in Treatment Resistant Depression
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Assessment of the Efficacy, Safety and Tolerability of CX157 Modified Release Tablet, 125 mg Twice Per Day in Subjects With Treatment Resistant Depression
Status: Archived
Updated: 1/1/1970
Synergy Clinical Research Center
mi
from
National City, CA
Efficacy, Safety and Tolerability of CX157 in Treatment Resistant Depression
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Assessment of the Efficacy, Safety and Tolerability of CX157 Modified Release Tablet, 125 mg Twice Per Day in Subjects With Treatment Resistant Depression
Status: Archived
Excell Research, Inc.
mi
from
Oceanside, CA
Efficacy, Safety and Tolerability of CX157 in Treatment Resistant Depression
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Assessment of the Efficacy, Safety and Tolerability of CX157 Modified Release Tablet, 125 mg Twice Per Day in Subjects With Treatment Resistant Depression
Status: Archived
Updated: 1/1/1970
Excell Research, Inc.
mi
from
Oceanside, CA
Efficacy, Safety and Tolerability of CX157 in Treatment Resistant Depression
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Assessment of the Efficacy, Safety and Tolerability of CX157 Modified Release Tablet, 125 mg Twice Per Day in Subjects With Treatment Resistant Depression
Status: Archived
Pacific Clinical Research
mi
from
Orange, CA
Efficacy, Safety and Tolerability of CX157 in Treatment Resistant Depression
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Assessment of the Efficacy, Safety and Tolerability of CX157 Modified Release Tablet, 125 mg Twice Per Day in Subjects With Treatment Resistant Depression
Status: Archived
Updated: 1/1/1970
Pacific Clinical Research
mi
from
Orange, CA
Efficacy, Safety and Tolerability of CX157 in Treatment Resistant Depression
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Assessment of the Efficacy, Safety and Tolerability of CX157 Modified Release Tablet, 125 mg Twice Per Day in Subjects With Treatment Resistant Depression
Status: Archived
Gulfcoast Clinical Research Center
mi
from
Fort Myers, FL
Efficacy, Safety and Tolerability of CX157 in Treatment Resistant Depression
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Assessment of the Efficacy, Safety and Tolerability of CX157 Modified Release Tablet, 125 mg Twice Per Day in Subjects With Treatment Resistant Depression
Status: Archived
Updated: 1/1/1970
Gulfcoast Clinical Research Center
mi
from
Fort Myers, FL
Efficacy, Safety and Tolerability of CX157 in Treatment Resistant Depression
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Assessment of the Efficacy, Safety and Tolerability of CX157 Modified Release Tablet, 125 mg Twice Per Day in Subjects With Treatment Resistant Depression
Status: Archived
Clinical Neuroscience Solutions, Inc.
mi
from
Jacksonville, FL
Efficacy, Safety and Tolerability of CX157 in Treatment Resistant Depression
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Assessment of the Efficacy, Safety and Tolerability of CX157 Modified Release Tablet, 125 mg Twice Per Day in Subjects With Treatment Resistant Depression
Status: Archived
Updated: 1/1/1970
Clinical Neuroscience Solutions, Inc.
mi
from
Jacksonville, FL
Efficacy, Safety and Tolerability of CX157 in Treatment Resistant Depression
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Assessment of the Efficacy, Safety and Tolerability of CX157 Modified Release Tablet, 125 mg Twice Per Day in Subjects With Treatment Resistant Depression
Status: Archived
The Segal Institute of Clinical Research
mi
from
North Miami, FL
Efficacy, Safety and Tolerability of CX157 in Treatment Resistant Depression
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Assessment of the Efficacy, Safety and Tolerability of CX157 Modified Release Tablet, 125 mg Twice Per Day in Subjects With Treatment Resistant Depression
Status: Archived
Updated: 1/1/1970
The Segal Institute of Clinical Research
mi
from
North Miami, FL
Efficacy, Safety and Tolerability of CX157 in Treatment Resistant Depression
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Assessment of the Efficacy, Safety and Tolerability of CX157 Modified Release Tablet, 125 mg Twice Per Day in Subjects With Treatment Resistant Depression
Status: Archived
Stedman Clinical Trials
mi
from
Tampa, FL
Efficacy, Safety and Tolerability of CX157 in Treatment Resistant Depression
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Assessment of the Efficacy, Safety and Tolerability of CX157 Modified Release Tablet, 125 mg Twice Per Day in Subjects With Treatment Resistant Depression
Status: Archived
Updated: 1/1/1970
Stedman Clinical Trials
mi
from
Tampa, FL
Efficacy, Safety and Tolerability of CX157 in Treatment Resistant Depression
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Assessment of the Efficacy, Safety and Tolerability of CX157 Modified Release Tablet, 125 mg Twice Per Day in Subjects With Treatment Resistant Depression
Status: Archived
University of South Florida College of Medicine Psychiatry Center
mi
from
Tampa, FL
Efficacy, Safety and Tolerability of CX157 in Treatment Resistant Depression
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Assessment of the Efficacy, Safety and Tolerability of CX157 Modified Release Tablet, 125 mg Twice Per Day in Subjects With Treatment Resistant Depression
Status: Archived
Updated: 1/1/1970
University of South Florida College of Medicine Psychiatry Center
mi
from
Tampa, FL
Efficacy, Safety and Tolerability of CX157 in Treatment Resistant Depression
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Assessment of the Efficacy, Safety and Tolerability of CX157 Modified Release Tablet, 125 mg Twice Per Day in Subjects With Treatment Resistant Depression
Status: Archived
Kolin Research Group
mi
from
Winter Park, FL
Efficacy, Safety and Tolerability of CX157 in Treatment Resistant Depression
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Assessment of the Efficacy, Safety and Tolerability of CX157 Modified Release Tablet, 125 mg Twice Per Day in Subjects With Treatment Resistant Depression
Status: Archived
Updated: 1/1/1970
Kolin Research Group
mi
from
Winter Park, FL
Efficacy, Safety and Tolerability of CX157 in Treatment Resistant Depression
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Assessment of the Efficacy, Safety and Tolerability of CX157 Modified Release Tablet, 125 mg Twice Per Day in Subjects With Treatment Resistant Depression
Status: Archived
Atlanta Institute of Medicine and Research
mi
from
Atlanta, GA
Efficacy, Safety and Tolerability of CX157 in Treatment Resistant Depression
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Assessment of the Efficacy, Safety and Tolerability of CX157 Modified Release Tablet, 125 mg Twice Per Day in Subjects With Treatment Resistant Depression
Status: Archived
Updated: 1/1/1970
Atlanta Institute of Medicine and Research
mi
from
Atlanta, GA
Efficacy, Safety and Tolerability of CX157 in Treatment Resistant Depression
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Assessment of the Efficacy, Safety and Tolerability of CX157 Modified Release Tablet, 125 mg Twice Per Day in Subjects With Treatment Resistant Depression
Status: Archived
Nathan Shapira, MD, Ph.D
mi
from
Smyrna, GA
Efficacy, Safety and Tolerability of CX157 in Treatment Resistant Depression
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Assessment of the Efficacy, Safety and Tolerability of CX157 Modified Release Tablet, 125 mg Twice Per Day in Subjects With Treatment Resistant Depression
Status: Archived
Updated: 1/1/1970
Nathan Shapira, MD, Ph.D
mi
from
Smyrna, GA
Efficacy, Safety and Tolerability of CX157 in Treatment Resistant Depression
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Assessment of the Efficacy, Safety and Tolerability of CX157 Modified Release Tablet, 125 mg Twice Per Day in Subjects With Treatment Resistant Depression
Status: Archived
McLean Hospital
mi
from
Belmont, MA
Efficacy, Safety and Tolerability of CX157 in Treatment Resistant Depression
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Assessment of the Efficacy, Safety and Tolerability of CX157 Modified Release Tablet, 125 mg Twice Per Day in Subjects With Treatment Resistant Depression
Status: Archived
Updated: 1/1/1970
McLean Hospital
mi
from
Belmont, MA
Efficacy, Safety and Tolerability of CX157 in Treatment Resistant Depression
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Assessment of the Efficacy, Safety and Tolerability of CX157 Modified Release Tablet, 125 mg Twice Per Day in Subjects With Treatment Resistant Depression
Status: Archived
AccelRx Research
mi
from
Fall River, MA
Efficacy, Safety and Tolerability of CX157 in Treatment Resistant Depression
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Assessment of the Efficacy, Safety and Tolerability of CX157 Modified Release Tablet, 125 mg Twice Per Day in Subjects With Treatment Resistant Depression
Status: Archived
Updated: 1/1/1970
AccelRx Research
mi
from
Fall River, MA
Efficacy, Safety and Tolerability of CX157 in Treatment Resistant Depression
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Assessment of the Efficacy, Safety and Tolerability of CX157 Modified Release Tablet, 125 mg Twice Per Day in Subjects With Treatment Resistant Depression
Status: Archived
Eastside Comprehensive Medical Center
mi
from
New York, NY
Efficacy, Safety and Tolerability of CX157 in Treatment Resistant Depression
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Assessment of the Efficacy, Safety and Tolerability of CX157 Modified Release Tablet, 125 mg Twice Per Day in Subjects With Treatment Resistant Depression
Status: Archived
Updated: 1/1/1970
Eastside Comprehensive Medical Center
mi
from
New York, NY
Efficacy, Safety and Tolerability of CX157 in Treatment Resistant Depression
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Assessment of the Efficacy, Safety and Tolerability of CX157 Modified Release Tablet, 125 mg Twice Per Day in Subjects With Treatment Resistant Depression
Status: Archived
Richard H. Weisler & Associates
mi
from
Raleigh, NC
Efficacy, Safety and Tolerability of CX157 in Treatment Resistant Depression
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Assessment of the Efficacy, Safety and Tolerability of CX157 Modified Release Tablet, 125 mg Twice Per Day in Subjects With Treatment Resistant Depression
Status: Archived
Updated: 1/1/1970
Richard H. Weisler & Associates
mi
from
Raleigh, NC
Efficacy, Safety and Tolerability of CX157 in Treatment Resistant Depression
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Assessment of the Efficacy, Safety and Tolerability of CX157 Modified Release Tablet, 125 mg Twice Per Day in Subjects With Treatment Resistant Depression
Status: Archived
Northcoast Clinical Trials
mi
from
Beachwood, OH
Efficacy, Safety and Tolerability of CX157 in Treatment Resistant Depression
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Assessment of the Efficacy, Safety and Tolerability of CX157 Modified Release Tablet, 125 mg Twice Per Day in Subjects With Treatment Resistant Depression
Status: Archived
Updated: 1/1/1970
Northcoast Clinical Trials
mi
from
Beachwood, OH
Efficacy, Safety and Tolerability of CX157 in Treatment Resistant Depression
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Assessment of the Efficacy, Safety and Tolerability of CX157 Modified Release Tablet, 125 mg Twice Per Day in Subjects With Treatment Resistant Depression
Status: Archived
Patient Priority Clinical sites, LLC
mi
from
Cincinnati, OH
Efficacy, Safety and Tolerability of CX157 in Treatment Resistant Depression
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Assessment of the Efficacy, Safety and Tolerability of CX157 Modified Release Tablet, 125 mg Twice Per Day in Subjects With Treatment Resistant Depression
Status: Archived
Updated: 1/1/1970
Patient Priority Clinical sites, LLC
mi
from
Cincinnati, OH
Efficacy, Safety and Tolerability of CX157 in Treatment Resistant Depression
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Assessment of the Efficacy, Safety and Tolerability of CX157 Modified Release Tablet, 125 mg Twice Per Day in Subjects With Treatment Resistant Depression
Status: Archived
North Star Medical Research, LLC
mi
from
Middleburg Heights, OH
Efficacy, Safety and Tolerability of CX157 in Treatment Resistant Depression
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Assessment of the Efficacy, Safety and Tolerability of CX157 Modified Release Tablet, 125 mg Twice Per Day in Subjects With Treatment Resistant Depression
Status: Archived
Updated: 1/1/1970
North Star Medical Research, LLC
mi
from
Middleburg Heights, OH
Efficacy, Safety and Tolerability of CX157 in Treatment Resistant Depression
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Assessment of the Efficacy, Safety and Tolerability of CX157 Modified Release Tablet, 125 mg Twice Per Day in Subjects With Treatment Resistant Depression
Status: Archived
Summitt Research Network (Oregon)
mi
from
Portland, OR
Efficacy, Safety and Tolerability of CX157 in Treatment Resistant Depression
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Assessment of the Efficacy, Safety and Tolerability of CX157 Modified Release Tablet, 125 mg Twice Per Day in Subjects With Treatment Resistant Depression
Status: Archived
Updated: 1/1/1970
Summitt Research Network (Oregon)
mi
from
Portland, OR
Efficacy, Safety and Tolerability of CX157 in Treatment Resistant Depression
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Assessment of the Efficacy, Safety and Tolerability of CX157 Modified Release Tablet, 125 mg Twice Per Day in Subjects With Treatment Resistant Depression
Status: Archived
Oregon Center for Clinical Investigations, Inc.
mi
from
Portland, OR
Efficacy, Safety and Tolerability of CX157 in Treatment Resistant Depression
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Assessment of the Efficacy, Safety and Tolerability of CX157 Modified Release Tablet, 125 mg Twice Per Day in Subjects With Treatment Resistant Depression
Status: Archived
Updated: 1/1/1970
Oregon Center for Clinical Investigations, Inc.
mi
from
Portland, OR
Efficacy, Safety and Tolerability of CX157 in Treatment Resistant Depression
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Assessment of the Efficacy, Safety and Tolerability of CX157 Modified Release Tablet, 125 mg Twice Per Day in Subjects With Treatment Resistant Depression
Status: Archived
Introspect of Buxmont
mi
from
Colmar, PA
Efficacy, Safety and Tolerability of CX157 in Treatment Resistant Depression
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Assessment of the Efficacy, Safety and Tolerability of CX157 Modified Release Tablet, 125 mg Twice Per Day in Subjects With Treatment Resistant Depression
Status: Archived
Updated: 1/1/1970
Introspect of Buxmont
mi
from
Colmar, PA
Efficacy, Safety and Tolerability of CX157 in Treatment Resistant Depression
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Assessment of the Efficacy, Safety and Tolerability of CX157 Modified Release Tablet, 125 mg Twice Per Day in Subjects With Treatment Resistant Depression
Status: Archived
Clinical Neurosciences Solutions, Inc.
mi
from
Memphis, TN
Efficacy, Safety and Tolerability of CX157 in Treatment Resistant Depression
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Assessment of the Efficacy, Safety and Tolerability of CX157 Modified Release Tablet, 125 mg Twice Per Day in Subjects With Treatment Resistant Depression
Status: Archived
Updated: 1/1/1970
Clinical Neurosciences Solutions, Inc.
mi
from
Memphis, TN
Efficacy, Safety and Tolerability of CX157 in Treatment Resistant Depression
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Assessment of the Efficacy, Safety and Tolerability of CX157 Modified Release Tablet, 125 mg Twice Per Day in Subjects With Treatment Resistant Depression
Status: Archived
Community Clinical Research
mi
from
Austin, TX
Efficacy, Safety and Tolerability of CX157 in Treatment Resistant Depression
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Assessment of the Efficacy, Safety and Tolerability of CX157 Modified Release Tablet, 125 mg Twice Per Day in Subjects With Treatment Resistant Depression
Status: Archived
Updated: 1/1/1970
Community Clinical Research
mi
from
Austin, TX
Efficacy, Safety and Tolerability of CX157 in Treatment Resistant Depression
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Assessment of the Efficacy, Safety and Tolerability of CX157 Modified Release Tablet, 125 mg Twice Per Day in Subjects With Treatment Resistant Depression
Status: Archived
FutureSearch Trials of Dallas
mi
from
Dallas, TX
Efficacy, Safety and Tolerability of CX157 in Treatment Resistant Depression
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Assessment of the Efficacy, Safety and Tolerability of CX157 Modified Release Tablet, 125 mg Twice Per Day in Subjects With Treatment Resistant Depression
Status: Archived
Updated: 1/1/1970
FutureSearch Trials of Dallas
mi
from
Dallas, TX
Efficacy, Safety and Tolerability of CX157 in Treatment Resistant Depression
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Assessment of the Efficacy, Safety and Tolerability of CX157 Modified Release Tablet, 125 mg Twice Per Day in Subjects With Treatment Resistant Depression
Status: Archived
Radiant Research
mi
from
Salt Lake City, UT
Efficacy, Safety and Tolerability of CX157 in Treatment Resistant Depression
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Assessment of the Efficacy, Safety and Tolerability of CX157 Modified Release Tablet, 125 mg Twice Per Day in Subjects With Treatment Resistant Depression
Status: Archived
Updated: 1/1/1970
Radiant Research
mi
from
Salt Lake City, UT
Efficacy, Safety and Tolerability of CX157 in Treatment Resistant Depression
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Assessment of the Efficacy, Safety and Tolerability of CX157 Modified Release Tablet, 125 mg Twice Per Day in Subjects With Treatment Resistant Depression
Status: Archived
Northwest Clinical Research Center
mi
from
East Seattle, WA
Efficacy, Safety and Tolerability of CX157 in Treatment Resistant Depression
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Assessment of the Efficacy, Safety and Tolerability of CX157 Modified Release Tablet, 125 mg Twice Per Day in Subjects With Treatment Resistant Depression
Status: Archived
Updated: 1/1/1970
Northwest Clinical Research Center
mi
from
East Seattle, WA
Efficacy, Safety and Tolerability of CX157 in Treatment Resistant Depression
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Assessment of the Efficacy, Safety and Tolerability of CX157 Modified Release Tablet, 125 mg Twice Per Day in Subjects With Treatment Resistant Depression
Status: Archived
Summit Research Network (Seattle) LLC
mi
from
Seattle, WA
Efficacy, Safety and Tolerability of CX157 in Treatment Resistant Depression
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Assessment of the Efficacy, Safety and Tolerability of CX157 Modified Release Tablet, 125 mg Twice Per Day in Subjects With Treatment Resistant Depression
Status: Archived
Updated: 1/1/1970
Summit Research Network (Seattle) LLC
mi
from
Seattle, WA
Efficacy, Safety and Tolerability of CX157 in Treatment Resistant Depression
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Assessment of the Efficacy, Safety and Tolerability of CX157 Modified Release Tablet, 125 mg Twice Per Day in Subjects With Treatment Resistant Depression
Status: Archived
Northbrooke Research Center
mi
from
Brown Deer, WI
Efficacy, Safety and Tolerability of CX157 in Treatment Resistant Depression
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Assessment of the Efficacy, Safety and Tolerability of CX157 Modified Release Tablet, 125 mg Twice Per Day in Subjects With Treatment Resistant Depression
Status: Archived
Updated: 1/1/1970
Northbrooke Research Center
mi
from
Brown Deer, WI
Safety and Efficacy of F2695 SR in Adults With Fatigue Associated With Major Depressive Disorder
A Double-blind, Randomized, Placebo- and Active-Controlled Study of F2695 SR in Adult Patients With Fatigue Associated With Major Depressive Disorder
Status: Archived
Forest Investigative Site 010
mi
from
Birmingham, AL
Safety and Efficacy of F2695 SR in Adults With Fatigue Associated With Major Depressive Disorder
A Double-blind, Randomized, Placebo- and Active-Controlled Study of F2695 SR in Adult Patients With Fatigue Associated With Major Depressive Disorder
Status: Archived
Updated: 1/1/1970
Forest Investigative Site 010
mi
from
Birmingham, AL
Safety and Efficacy of F2695 SR in Adults With Fatigue Associated With Major Depressive Disorder
A Double-blind, Randomized, Placebo- and Active-Controlled Study of F2695 SR in Adult Patients With Fatigue Associated With Major Depressive Disorder
Status: Archived
Forest Investigative Site 002
mi
from
Little Rock, AR
Safety and Efficacy of F2695 SR in Adults With Fatigue Associated With Major Depressive Disorder
A Double-blind, Randomized, Placebo- and Active-Controlled Study of F2695 SR in Adult Patients With Fatigue Associated With Major Depressive Disorder
Status: Archived
Updated: 1/1/1970
Forest Investigative Site 002
mi
from
Little Rock, AR
Safety and Efficacy of F2695 SR in Adults With Fatigue Associated With Major Depressive Disorder
A Double-blind, Randomized, Placebo- and Active-Controlled Study of F2695 SR in Adult Patients With Fatigue Associated With Major Depressive Disorder
Status: Archived
Forest Investigative Site 01
mi
from
Escondido, CA
Safety and Efficacy of F2695 SR in Adults With Fatigue Associated With Major Depressive Disorder
A Double-blind, Randomized, Placebo- and Active-Controlled Study of F2695 SR in Adult Patients With Fatigue Associated With Major Depressive Disorder
Status: Archived
Updated: 1/1/1970
Forest Investigative Site 01
mi
from
Escondido, CA